Rechallenging with anthracyclines and taxanes in metastatic breast cancer

  • Palmieri C
  • Krell J
  • James C
 et al. 
  • 30

    Readers

    Mendeley users who have this article in their library.
  • 30

    Citations

    Citations of this article.

Abstract

Adjuvant use of anthracycline-taxane combination therapy is an accepted strategy in the management of high-risk early-stage breast cancer. However, the introduction of this regimen raises the question of how best to manage those patients who relapse following adjuvant therapy, and whether there is a role for rechallenging in the metastatic setting with the same agent, or class of agent, that has been utilized in the adjuvant setting. This Review examines the evidence for rechallenging with both anthracyclines and taxanes, and highlights the issues that need to be examined in the context of future clinical trials.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Carlo Palmieri

  • Jonathan Krell

  • Colin R. James

  • Catherine Harper-Wynne

  • Vivek Misra

  • Susan Cleator

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free